Arthur Amani, Johnston Edward W, Winfield Jessica M, Blackledge Matthew D, Jones Robin L, Huang Paul H, Messiou Christina
Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, United Kingdom.
Sarcoma Unit, The Royal Marsden National Health Service (NHS) Foundation Trust, London, United Kingdom.
Front Oncol. 2022 Jul 1;12:892620. doi: 10.3389/fonc.2022.892620. eCollection 2022.
A shift in radiology to a data-driven specialty has been unlocked by synergistic developments in imaging biomarkers (IB) and computational science. This is advancing the capability to deliver "virtual biopsies" within oncology. The ability to non-invasively probe tumour biology both spatially and temporally would fulfil the potential of imaging to inform management of complex tumours; improving diagnostic accuracy, providing new insights into inter- and intra-tumoral heterogeneity and individualised treatment planning and monitoring. Soft tissue sarcomas (STS) are rare tumours of mesenchymal origin with over 150 histological subtypes and notorious heterogeneity. The combination of inter- and intra-tumoural heterogeneity and the rarity of the disease remain major barriers to effective treatments. We provide an overview of the process of successful IB development, the key imaging and computational advancements in STS including quantitative magnetic resonance imaging, radiomics and artificial intelligence, and the studies to date that have explored the potential biological surrogates to imaging metrics. We discuss the promising future directions of IBs in STS and illustrate how the routine clinical implementation of a virtual biopsy has the potential to revolutionise the management of this group of complex cancers and improve clinical outcomes.
成像生物标志物(IB)和计算科学的协同发展开启了放射学向数据驱动专业的转变。这正在提高肿瘤学中提供“虚拟活检”的能力。在空间和时间上对肿瘤生物学进行无创探测的能力将实现成像在复杂肿瘤管理中的潜力;提高诊断准确性,为肿瘤间和肿瘤内异质性以及个体化治疗规划与监测提供新见解。软组织肉瘤(STS)是间充质起源的罕见肿瘤,有超过150种组织学亚型且具有显著的异质性。肿瘤间和肿瘤内异质性以及该疾病的罕见性相结合,仍然是有效治疗的主要障碍。我们概述了成功开发IB的过程、STS中的关键成像和计算进展,包括定量磁共振成像、放射组学和人工智能,以及迄今为止探索成像指标潜在生物学替代物的研究。我们讨论了IB在STS中充满希望的未来方向,并说明了虚拟活检的常规临床应用如何有可能彻底改变这组复杂癌症的管理并改善临床结果。